Name:
In Focus: Minimal Residual Disease in multiple myeloma
Description:
In Focus: Minimal Residual Disease in multiple myeloma
Thumbnail URL:
https://cadmoremediastorage.blob.core.windows.net/2d0cc290-93ac-4311-bdf2-d290657c38c2/videoscrubberimages/Scrubber_15.jpg
Duration:
T00H01M53S
Embed URL:
https://stream.cadmore.media/player/2d0cc290-93ac-4311-bdf2-d290657c38c2
Content URL:
https://cadmoreoriginalmedia.blob.core.windows.net/2d0cc290-93ac-4311-bdf2-d290657c38c2/Animated Video Final No US job code.mp4?sv=2019-02-02&sr=c&sig=mpneDayI1dS0pOJiUdEcjzhvcmL2qW2B9equyTBzkkQ%3D&st=2024-05-11T06%3A13%3A46Z&se=2024-05-11T08%3A18%3A46Z&sp=r
Upload Date:
2023-01-16T00:00:00.0000000
Transcript:
Language: EN.
Segment:0 .
[MUSIC PLAYING]
SPEAKER: Minimal residual disease, or MRD, refers to the malignant cells that persist in the bone marrow after treatment but cannot be detected with conventional response measures like complete response. These cells can proliferate and ultimately lead to relapse. As advances in treatment have led to deeper responses and higher rates of complete response, more sensitive techniques are needed to evaluate for residual disease after therapy. MRD negativity is currently the deepest level of treatment response that can be measured in multiple myeloma.
SPEAKER: A person who is MRD negative has an undetectable level of malignant cells in the bone marrow with a minimum sensitivity threshold of 10 to the negative 5. Achieving MRD negativity after treatment has been associated with longer progression-free survival and overall survival. It's important to evaluate new therapies based on their ability to drive patients to MRD negativity.
SPEAKER: MRD negativity rates achieved in clinical trials can serve as an indicator of the potency and long-term efficacy of new regimens. In this feature, we will be focusing on MRD negativity as a measure of treatment response, as a goal in frontline therapy, and as a meaningful indicator of improved long-term outcomes in multiple myeloma.